Starbucks denies that its decision to stop selling Chicken, Maple Butter, and Egg Sandwich on June 26, a mere five days after it had been announced as a new permanent menu item, was due to FDA recall or salmonella or listeria contamination.
A Starbucks spokesperson said that the Chicken, Maple Butter, and Egg Sandwich was given a voluntary stop sell and discard order by the company because it didn't live up to the company's high standards for quality.
The quality issue that was identified by Starbucks was simply about taste or based on another issue and would not lead to food-borne illness and any reports linking the stop sale to illness are inaccurate.
The spokesperson added that Starbucks is devoted to providing high-quality products, and anytime a concern about a product or its quality is expressed, we always proceed with extreme caution.


Columbia Student Mahmoud Khalil Fights Arrest as Deportation Case Moves to New Jersey
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Locked up then locked out: how NZ’s bank rules make life for ex-prisoners even harder
How to support someone who is grieving: five research-backed strategies
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
What’s the difference between baking powder and baking soda? It’s subtle, but significant
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Why financial hardship is more likely if you’re disabled or sick
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



